Home › Funds › BRAIDWELL LP › DNTH
BRAIDWELL LP position in DNTH
DIANTHUS THERAPEUTICS INC COM · Health Care
BRAIDWELL LP reported holding 594,562 shares of DNTH (DIANTHUS THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$58.0M, representing 2.28% of its reported portfolio and ranking #10 among its reported holdings. BRAIDWELL LP has disclosed DNTH holdings in 8 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's DNTH position evolved
BRAIDWELL LP first disclosed a stake in DNTH in Q2 2024 at 366,851 shares (US$9.5M). The position peaked in Q1 2026 at 899,364 shares, worth US$75.5M. Across 8 filings, BRAIDWELL LP increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 594,562 shares valued at US$58.0M — a reduction of -304,802 shares quarter over quarter.. Notable position changes include a 144% increase in Q4 2024 (shares fell 17% over the following quarter), a 69% trim in Q1 2025 (shares rose 3% over the following quarter), a 53% increase in Q4 2025 (shares rose 104% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 366.85K | $9.49M | New |
| Q3 2024 | 493.69K | $13.52M | Add |
| Q4 2024 | 1.21M | $26.30M | Add |
| Q1 2025 | 375.36K | $6.81M | Reduce |
| Q3 2025 | 835.06K | $32.86M | New |
| Q4 2025 | 1.27M | $52.50M | Add |
| Q1 2026 | 899.36K | $75.47M | Reduce |
| Q2 2026 | 594.56K | $57.96M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNTH and 13F data
DNTH (DIANTHUS THERAPEUTICS INC COM) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNTH
- Fairmount Funds Management LLC 2.54M sh · $247.33M · Q2 2026
- Avidity Partners Management LP 2.10M sh · $205.12M · Q2 2026
- Octagon Capital Advisors LP 1.84M sh · $179.53M · Q2 2026
- TCG Crossover Management, LLC 1.68M sh · $163.44M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 1.30M sh · $126.97M · Q2 2026
- Venrock Adviser, LLC 1.18M sh · $115.03M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.13M sh · $109.70M · Q2 2026
- BAKER BROS. ADVISORS LP 852.16K sh · $83.07M · Q2 2026
- Logos Global Management LP 800.00K sh · $77.98M · Q2 2026
- Cormorant Asset Management, LP 750.00K sh · $73.11M · Q2 2026
- MPM BioImpact LLC 420.00K sh · $40.94M · Q2 2026
- Affinity Asset Advisors, LLC 400.00K sh · $38.99M · Q2 2026
FAQ
How long has BRAIDWELL LP held DNTH?
BRAIDWELL LP has disclosed DNTH holdings in 8 of the last 9 reported quarters, going back to Q2 2024.
What is BRAIDWELL LP's current position in DNTH?
As of Q2 2026, BRAIDWELL LP holds 594.56K shares of DNTH (DIANTHUS THERAPEUTICS INC COM), valued at $57.96M, representing 2.28% of its reported portfolio and ranking #10.
Has BRAIDWELL LP been buying or selling DNTH?
In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in DNTH. The position peaked in Q1 2026 at 899.36K shares.
Which other funds hold DNTH?
Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 72 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.